AstraZeneca Industries

As of December 2020, the main activity is the production of drugs and materials used for medical purposes.

Performance indicators

2022: Revenue growth to a new record of 23.61 billion rubles, profit - up to 2.18 billion rubles

In 2022, AstraZeneca Industries LLC received revenue of 23.61 billion rubles against 14.92 billion rubles a year earlier. The net profit of the Russian plant of the Swedish-British biopharmaceutical company AstraZeneca in comparison with these periods rose by 36.7% - from 1.59 billion to 2.18 billion rubles. Such data were released at the end of April 2023.

According to Interfax, citing materials from AstraZeneca Industries LLC, the company's revenue in 2022 was a record, and net profit was the second largest in history. The maximum profit was dated 2020, when it amounted to 2.99 billion rubles.

AstraZeneca Industries LLC Vorsino Plant

The company's accounts payable in 2022 reached 11.24 billion rubles against 6.92 billion rubles a year earlier, receivables - 13.77 billion rubles against 10.42 billion rubles in 2021.

The AstraZeneca Industries LLC plant in Vorsino (Kaluga Region) has a capacity of 40 million packages, or 850 million tablets per year (data at the end of December 2022).

In 2022, AstraZeneca continued to work in Russia, despite the fact that a large number of foreign companies left the market after the start of a special operation of the Russian Federation in Ukraine.

AstraZeneca continues to operate in Russia and is taking all necessary measures to ensure uninterrupted supplies of medicines, as well as continuous production at the company's plant in the Kaluga region, the manufacturer said in a statement.

The company also noted that it is doing everything possible to support ongoing projects, including providing patients with medicines, their production, scientific and educational activities and clinical research. AstraZeneca has been present on the Russian market since 1993.^[1]

Notes